. 2012 Jun;4(3):159–166. doi: 10.1177/1759720X12441274

Table 1.

Early morning stiffness duration and interleukin-6 data for the CAPRA-1 trial and open-label extension.

		EMS (min)		IL-6 (IU/L)
		MR prednisone	IR prednisone	MR prednisone	IR prednisone
Baseline	Mean (SD)	164.1 (101.4) n = 125	182.5 (125.0) n = 129
	Median (range)	146.6 (13.6–659.3) n = 125	152.9 (32.1–720) n = 129	860 (200–23,000) n = 142	1110 (200–20,800) n = 142
Absolute change at 3 months (end of double-blind phase)	Mean (SD)	−43.96^*(136.6) n = 125	−22.68 (138.1) n = 129
	Median (range)	−39.3 (−537.6–600) n = 125	−21.5 (−586.3–618.6) n = 129	−160^* (−13,460.0–9080.0) n = 135	0 (−16,190.0– 18,100.0) n = 132

		MR/MR group	IR/MR group	MR/MR group	IR/MR group

Absolute change at 12 months (end of open phase)	Mean (SD)	83 (83.7) n =103	88 (128.3) n = 114
	Median (range)			−390^* (200–18,300) n = 103	−595^* (200–8100) n = 114

Adapted from Buttgereit et al. [2008, 2010]. *Indicates statistically significant results (p < 0.05). EMS, early morning stiffness; IL-6, interleukin-6; IR, immediate release; MR, modified release; SD, standard deviation.